Radiopharmaceuticals for Skeletal Muscle PET Imaging

被引:2
|
作者
Park, Joo Yeon [1 ]
Park, Sun Mi [1 ]
Lee, Tae Sup [2 ]
Kang, Seo Young [1 ]
Kim, Ji-Young [1 ]
Yoon, Hai-Jeon [1 ]
Kim, Bom Sahn [1 ]
Moon, Byung Seok [1 ]
机构
[1] Ewha Womans Univ, Coll Med, Dept Nucl Med, Seoul 07804, South Korea
[2] Korea Inst Radiol & Med Sci, Div RI Applicat, Seoul 01812, South Korea
基金
新加坡国家研究基金会;
关键词
positron emission tomography; radiopharmaceutical; skeletal muscle atrophy; GLUCOSE-UPTAKE; BLOOD-FLOW; MANAGEMENT; MECHANISMS;
D O I
10.3390/ijms25094860
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The skeletal muscles account for approximately 40% of the body weight and are crucial in movement, nutrient absorption, and energy metabolism. Muscle loss and decline in function cause a decrease in the quality of life of patients and the elderly, leading to complications that require early diagnosis. Positron emission tomography/computed tomography (PET/CT) offers non-invasive, high-resolution visualization of tissues. It has emerged as a promising alternative to invasive diagnostic methods and is attracting attention as a tool for assessing muscle function and imaging muscle diseases. Effective imaging of muscle function and pathology relies on appropriate radiopharmaceuticals that target key aspects of muscle metabolism, such as glucose uptake, adenosine triphosphate (ATP) production, and the oxidation of fat and carbohydrates. In this review, we describe how [18F]fluoro-2-deoxy-D-glucose ([18F]FDG), [18F]fluorocholine ([18F]FCH), [11C]acetate, and [15O]water ([15O]H2O) are suitable radiopharmaceuticals for diagnostic imaging of skeletal muscles.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] PET/CT imaging of skeletal muscle metastases
    Surov, Alexey
    Pawelka, Maria Kerstin
    Wienke, Andreas
    Schramm, Dominik
    ACTA RADIOLOGICA, 2014, 55 (01) : 101 - 106
  • [2] PET radiopharmaceuticals for neuroreceptor imaging
    S. M. AMETAMEY
    P. A. SCHUBIGER
    Nuclear Science and Techniques, 2006, (03) : 143 - 147
  • [3] Imaging of NETs with PET radiopharmaceuticals
    Ambrosini, V.
    Tomassetti, P.
    Franchi, R.
    Fanti, S.
    QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 54 (01): : 16 - 23
  • [4] Radiopharmaceuticals for PET imaging of neuroinflammation
    Dupont, A. C.
    Guilloteau, D.
    Kassiou, M.
    Ribeiro, M. J.
    Vercouillie, J.
    Katsifis, A.
    Arlicot, N.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2016, 40 (01): : 72 - 81
  • [5] Skeletal Muscle Metastases on FDG PET/CT Imaging
    Khandelwal, Alok R.
    Takalkar, Amol M.
    Lilien, David L.
    Ravi, Ajay
    CLINICAL NUCLEAR MEDICINE, 2012, 37 (06) : 575 - 579
  • [6] PET radiopharmaceuticals for metabolic imaging in oncology
    Wiebe, LI
    PET AND MOLECULAR IMAGING: STATE OF THE ART AND FUTURE PERSPECTIVES, 2004, 1264 : 53 - 76
  • [7] Update on PET Radiopharmaceuticals for Imaging Hepatocellular Carcinoma
    Nyakale, Nozipho
    Filippi, Luca
    Aldous, Colleen
    Sathekge, Mike
    CANCERS, 2023, 15 (07)
  • [8] Metal based radiopharmaceuticals for pet imaging and radiotherapy
    Anderson, CJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1996, 212 : 5 - NUCL
  • [9] PET Radiopharmaceuticals for Prostate Cancer Imaging: A Review
    Fernandes, F.
    da Silva, D.
    Rodrigues, L.
    MEDICAL PHYSICS, 2015, 42 (06) : 3261 - 3261
  • [10] New PET Radiopharmaceuticals as Molecular Imaging Probes
    Vallabhajosula, Shankar
    SEMINARS IN NUCLEAR MEDICINE, 2011, 41 (04) : 244 - 245